Hospitalizations of Children and Adolescents with Laboratory-Confirmed COVID-19 — COVID-NET, 14 States, July 2021–January 2022

Marks, Kristin J.; Whitaker, Michael; Anglin, Onika; Milucky, Jennifer; Patel, Kadam; Pham, Huong; Chai, Shua J.; Kirley, Pam Daily; Armistead, Isaac; McLafferty, Sarah; Meek, James; Yousey‐Hindes, Kimberly; Anderson, Evan J.; Openo, Kyle P.; Weigel, Andy; Henderson, Justin; Nunez, Val Tellez; Como‐Sabetti, Kathryn; Lynfield, Ruth; Ropp, Susan L.; Smelser, Chad; Barney, Grant; Muse, Alison; Bennett, Nancy M.; Bushey, Sophrena; Billing, Laurie M; Shiltz, Eli; Abdullah, Nasreen; Sutton, Melissa; Schaffner, William; Talbot, H. Keipp; Chatelain, Ryan; George, Andrea; Taylor, Christopher A.; McMorrow, Meredith; Perrine, Cria G.; Havers, Fiona

doi:10.15585/mmwr.mm7107e4

Cited by 176 publications

(191 citation statements)

References 9 publications

Supporting

Mentioning

173

Contrasting

Unclassified

Order By: Relevance

“…Additional data are needed to fully-understand VE trends against severe disease. 2,9 By the end of January, 12.5% of vaccinated children 12-17 years had received a booster, likely adding protection to that group, although the time-since-vaccination analysis had no boosted children. This analysis compared early vaccinators in the younger age group withlater vaccinators in the older age group, who may differ in test-seeking or exposures.…”

Section: Discussionmentioning

confidence: 99%

“…Randomized trails and observational studies conducted during the Delta and earlier variants' predominance, indicate the BNT162b2 vaccine, developed to protect against original strains, is safe and effective in preventing COVID-19 outcomes in those 5-17 years and older. [1][2][3][4][5][6][7][8][9][10] Compared to children 12-17 years, who receive two 30g doses, less is known known about real-world vaccine effectiveness against infection and hospitalization effectiveness for children 5-11 years, who receive two 10g doses, particularly after the Omicron variant's emergence. 11,12 We examined the effectiveness of vaccination during the Omicron variant surge that began in early December 2021 on infection and hospitalization among children 5-11 years compared to 12-17 years using NYS statewide surveillance systems.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Effectiveness of the BNT162b2 vaccine among children 5-11 and 12-17 years in New York after the Emergence of the Omicron Variant

Dorabawila

Hoefer

Bauer

et al. 2022

Preprint

View full text Add to dashboard Cite

Importance: There is limited evidence on the effectiveness of the BNT162b2 vaccine for children, particularly those 5-11 years and after the Omicron variant's emergence. Objective: To estimate BNT162b2 vaccine effectiveness against COVID cases and hospitalizations among children 5-11 years and 12-17 years during December, 2021 and January, 2022. Design: Analyses of cohorts constructed from linked statewide immunization, laboratory testing, and hospitalization databases. Setting/Participants: New York State children 5-17 years. Main outcomes/measures: New laboratory-confirmed COVID-19 cases and hospitalizations. Comparisons were made using the incidence rate ratio (IRR), comparing outcomes by vaccination status, and estimated vaccine effectiveness (VE: 1-[1/IRR]). Results: From December 13, 2021 to January 30, 2022, among 852,384 fully-vaccinated children 12-17 years and 365,502 children 5-11 years, VE against cases declined from 66% (95% CI: 64%, 67%) to 51% (95% CI: 48%, 54%) for those 12-17 years and from 68% (95% CI: 63%, 72%) to 12% (95% CI: 6%, 16%) for those 5-11 years. During the January 24-30 week, VE for children 11 years was 11% (95%CI -3%, 23%) and for those age 12 was 67% (95% CI: 62%, 71%). VE against hospitalization declined changed from 85% (95% CI: 63%, 95%) to 73% (95% CI: 53%, 87%) for children 12-17 years, and from 100% (95% CI: -189%, 100%) to 48% (95% CI: -12%, 75%) for those 5-11 years. Among children newly fully-vaccinated December 13, 2021 to January 2, 2022, VE against cases within two weeks of full vaccination for children 12-17 years was 76% (95% CI: 71%, 81%) and by 28-34 days it was 56% (95% CI: 43%, 63%). For children 5-11, VE against cases declined from 65% (95% CI: 62%, 68%) to 12% (95% CI: 8%, 16%) by 28-34 days. Conclusions and Relevance: In the Omicron era, the effectiveness against cases of BNT162b2 declined rapidly for children, particularly those 5-11 years. However, vaccination of children 5-11 years was protective against severe disease and is recommended. These results highlight the potential need to study alternative vaccine dosing for children and the continued importance layered protections, including mask wearing, to prevent infection and transmission.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Effectiveness of the BNT162b2 vaccine among children 5-11 and 12-17 years in New York after the Emergence of the Omicron Variant

Dorabawila

Hoefer

Bauer

et al. 2022

Preprint

View full text Add to dashboard Cite

show abstract

“…The B.1.1.529 (Omicron) variant of SARS-CoV-2, the virus that causes COVID-19, has been the predominant circulating variant in the United States since late December 2021. * Coinciding with increased Omicron circulation, COVID-19–associated hospitalization rates increased rapidly among infants and children aged 0–4 years, a group not yet eligible for vaccination ( 1 ). Coronavirus Disease 19–Associated Hospitalization Surveillance Network (COVID-NET) † data were analyzed to describe COVID-19–associated hospitalizations among U.S. infants and children aged 0–4 years since March 2020.…”

mentioning

confidence: 99%

Hospitalization of Infants and Children Aged 0–4 Years with Laboratory-Confirmed COVID-19 — COVID-NET, 14 States, March 2020–February 2022

Marks¹,

Whitaker²,

Agathis³

et al. 2022

MMWR Morb. Mortal. Wkly. Rep.

Self Cite

155

176

View full text Add to dashboard Cite

“…Last, this analysis assessed COVID-19-associated hospitalization rates during a single year of the ongoing COVID-19 pandemic and did not capture all rate fluctuations that have occurred due to the changing epidemiology of SARS-CoV-2, including the emergence of variants of concern. The omicron variant of SARS-CoV-2 emerged rapidly during December 2021 and resulted in a peak weekly hospitalization rate approximately five times as high as the peak hospitalization rate during the period of Delta variant predominance among children 0–4 years old, a group not yet eligible for COVID-19 vaccination [40].…”

Section: Discussionmentioning

confidence: 99%

Comparison of influenza and COVID-19–associated hospitalizations among children < 18 years old in the United States — FluSurv-NET (October–April 2017–2021) and COVID-NET (October 2020–September 2021)

Delahoy

Ujamaa

Taylor

et al. 2022

Preprint

Self Cite

View full text Add to dashboard Cite

Background: Influenza virus and SARS-CoV-2 are significant causes of respiratory illness in children. Methods: Influenza and COVID-19-associated hospitalizations among children <18 years old were analyzed from FluSurv-NET and COVID-NET, two population-based surveillance systems with similar catchment areas and methodology. The annual COVID-19-associated hospitalization rate per 100 000 during the ongoing COVID-19 pandemic (October 1, 2020-September 30, 2021) was compared to influenza-associated hospitalization rates during the 2017-18 through 2019-20 influenza seasons. In-hospital outcomes, including intensive care unit (ICU) admission and death, were compared. Results: Among children <18 years old, the COVID-19-associated hospitalization rate (48.2) was higher than influenza-associated hospitalization rates: 2017-18 (33.5), 2018-19 (33.8), and 2019-20 (41.7). The COVID-19-associated hospitalization rate was higher among adolescents 12-17 years old (COVID-19: 59.9; influenza range: 12.2-14.1), but similar or lower among children 5-11 (COVID-19: 25.0; influenza range: 24.3-31.7) and 0-4 (COVID-19: 66.8; influenza range: 70.9-91.5) years old. Among children <18 years old, a higher proportion with COVID-19 required ICU admission compared with influenza (26.4% vs 21.6%; p<0.01). Pediatric deaths were uncommon during both COVID-19- and influenza-associated hospitalizations (0.7% vs 0.5%; p=0.28). Conclusions: In the setting of extensive mitigation measures during the COVID-19 pandemic, the annual COVID-19-associated hospitalization rate during 2020-2021 was higher among adolescents and similar or lower among children <12 years old compared with influenza during the three seasons before the COVID-19 pandemic. COVID-19 adds substantially to the existing burden of pediatric hospitalizations and severe outcomes caused by influenza and other respiratory viruses.

show abstract

Hospitalizations of Children and Adolescents with Laboratory-Confirmed COVID-19 — COVID-NET, 14 States, July 2021–January 2022

Cited by 176 publications

References 9 publications

Effectiveness of the BNT162b2 vaccine among children 5-11 and 12-17 years in New York after the Emergence of the Omicron Variant

Effectiveness of the BNT162b2 vaccine among children 5-11 and 12-17 years in New York after the Emergence of the Omicron Variant

Hospitalization of Infants and Children Aged 0–4 Years with Laboratory-Confirmed COVID-19 — COVID-NET, 14 States, March 2020–February 2022

Comparison of influenza and COVID-19–associated hospitalizations among children < 18 years old in the United States — FluSurv-NET (October–April 2017–2021) and COVID-NET (October 2020–September 2021)

Contact Info

Product

Resources

About